Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study

This study is an exploratory study, and all the drugs involved are listed drugs. The dosage of mirabetron is selected according to the basis of previous research. The clinical recommend dose of this product is 50mg/day, and the dose used in this study is 100mg/day, which is larger than the clinical commonly used dose. The main adverse reactions of this product are urinary tract infection and rapid heartbeat. In the clinical study, we will focus on the urine routine and heart-related adverse events of the subjects, and deal with the adverse events in time. Subjects were given mirabeeron 100mg/

Trial Details

NCT ID
NCT06534762
Phase
PHASE2
Sponsor
Zhejiang Provincial People's Hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • Mirabegron
Locations (sample)
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • Patients voluntarily participate in the study, sign informed consent, and have good compliance;
  • 18-65 years old (including 18 and 65 years old);
  • solid tumors confirmed by histology and/or cytology, and advanced metastatic tumors that are not feasible for surgical resection;
  • Has not received previous systemic antitumor drug therapy for metastatic/recurrent solid tumors;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →